ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2010 > Educational Cancer Convention Lugano - What is New in Haemato-Oncology?
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Educational Cancer Convention Lugano - What is New in Haemato-Oncology?

12 ESCO credits

17.04.2010  -  18.04.2010

Lugano, Switzerland


Haemato-oncology, Leukaemia, Lymphoma


On behalf of ESO and of the Scientific Committee, I have the pleasure of  inviting you to attend the Educational Cancer Convention Lugano.
The 2010 edition will be devoted to haemato-oncology with a programme developed in co-operation with the International Conference on Malignant Lymphoma and the International Extranodal Lymphoma Study Group.

The synergy between these entities has been devised to provide an overview of the latest developments in the field. In particular, the internationally renowned faculty will offer:
• 3 keynote lectures dealing with relevant biological and clinical aspects of leukaemias and lymphomas
• 4 main sessions addressing malignant lymphomas in general, extranodal lymphomas in particular, myeloma and chronic and acute leukaemias
• Ample time to discuss clinical cases presented both by the faculty and the participants
• Enhanced interactivity during poster discussion sessions

I look forward to welcome you to ECCLU 2010 and to your active participation.

Franco Cavalli

F. Cavalli, Chair, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Costa, ESO Director, Bellinzona and Milan, CH and IT
M.F. Fey, University Hospital, Berne, CH
T.A. Lister, St. Bartholomew's Hospital, London, UK
B. Lowenberg, Erasmus University Medical Centre, Rotterdam, NL
R.A. Stahel, University Hospital, Zurich, CH
P.L. Zinzani, Institute of Hematology "L. e A. Seràgnoli ", University of Bologna, Bologna, IT
E. Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

General information


European School of Oncology
Bellinzona Office

Ospedale Regionale Bellinzona e Valli
CH-6500 Bellinzona, Switzerland
Tel: +41 91 811 8050 - Fax: +41 91 811 8051

ESO Head Office
Via del Bollo 4 - 20123 Milano, Italy
Tel: +39 02 8546 451 - Fax +39 02 8546 4545

Programme and organisation
Chatrina Melcher - ESO Bellinzona 
Abstracts and programme
Dolores Knupfer - ESO Bellinzona
Registration Dept.


29 January 2010
     Abstract submission
26 February 2010   Early registration
31 March 2010        Late registration

Palazzo dei Congressi,
Lugano, Switzerland
Lugano is reachable by plane via Zurich (45-minute flight or 2,5-hour train) or from Milano Malpensa airport (2-hour drive, shuttleservice).

How to reach Lugano:

AirplaneLugano-Agno Airport (LUG) is located at 6 km from the town and it is the ideal point of arrival. A shuttle service to/from the centre and hotels is available. Please visit http://www.shuttle-bus.com/ for further information.
TrainFast and easy connections by train are available to Zurich (3 hours) or to Milan Central Station (not airport!).

Milano Malpensa

The transfer from the Milano Malpensa airport to Lugano takes approximately 1 hour and 15 minutes. Please note that booking is required. More information on schedule, duration, cost and booking form for the transfer are available at https://malpensaexpress.ch or www.starstation.ch  

The official language of the convention will be English. No simultaneous translation will be provided.

The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.

The organisers bear no responsibility for untoward events in relation with the participation in the Convention. Participants are advised to take out their own personal and travel insurance coverage.

All participants will be issued a certificate of attendance at the close of the Convention.
ECCLU has been appraised and approved by the Accreditation Council of Oncology in Europe (ACOE) acknowledging the quality of the scientific programme and its educational value.
ACOE is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The “Educational Cancer Convention Lugano – ECCLU: What is new in haemato-oncology?” is designated for a maximum of 10 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, the participant should contact the AMA. The programme is furthermore accredited with 11 ESMO-MORA category 1 points.

The yearly meeting of IELSG will take place in Lugano before the opening of ECCLU, on Friday 16 April. For registration and further information on the IELSG meeting, please visit

A limited number of travel grants are assigned on a competitive basis from among participants from middle-low income countries who have had an abstract accepted for oral or for poster presentation. The curriculum vitae should be submitted at the same time as the abstract (deadline: 29 January) indicating the amount requested to cover economy fare. Successful applicants will be granted registration, accommodation for 2 nights and refund of actual travel costs (flight only) at the end of the Convention.

ESO is grateful to the City of Lugano for their interest and continuous support in the organisation of ECCLU, to ESMO fortheir co-operation and support of travel grants. ESO is furthermore grateful to the International Conference on Malignant Lymphoma and to the International Extranodal Lymphoma Study Group for their commitment and devotion in defining the high-level programme.

The abstract book will be published as a supplement to the European Journal of Cancer and will contain abstracts of the invited lectures and those submitted by the participants that have been accepted for oral or poster presentation.


Faculty list


J.O. Armitage, University of Nebraska Medical Center, Department of Oncology and Hematology, Omaha, US
T. Barbui, Ospedali Riuniti di Bergamo, Division of Haematology, Bergamo, IT
F. Cavalli, Oncology Institute of Southern Switzerland, Medical Director, Bellinzona, CH
A. Costa, European School of Oncology, Scientific Director, Bellinzona, CH and Milan, IT
R. Dalla Favera, Herbert Irving Comprehensive Cancer Center, Columbia University, Department of Pathology and Genetics, New York, US
M. Dreyling, University Hospital Grosshadern, Department of Haemato-Oncology, Munich, DE
A. J.M. Ferreri, San Raffaele Scientific Institute, Department of Oncology, Lymphoid Malignancies Unit, Milan, IT
M.F. Fey, University of Berne, Clinic for Medical Oncology, Berne, CH
M. Ghielmini, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
M. Gospodarowicz, Princess Margaret Hospital - University of Toronto, Department of Radiation Oncology, Toronto, CA
M. Hallek, University Clinic Cologne, Department of Haematology, Cologne, DE
P.W.M. Johnson, Southampton General Hospital, Cancer Research UK Centre, Somers Cancer Research, Southampton, UK
T.A. Lister, St. Bartholomew's Hospital, Department of Medical Oncology, London, UK
B. Lowenberg, Erasmus University Medical Centre, Department of Haematology, Rotterdam, NL
A. Palumbo, University of Turin, Molinette Hospital, Department of Haematology, Turin, IT
M. Ponzoni, San Raffaele Scientific Institute, Pathology Unit, Milan, IT
G. Salles, Centre Hospitalier Lyon Sud, Department of Haematology, Lyon Pierre Benite, FR
R.A. Stahel, University Hospital Zurich, Clinic and Policlinic for Oncology, Zurich, CH
C. Thieblemont, Saint Louis Hospital, Department of Haemato-Oncology, Paris, FR
U. Vitolo, Ospedale Maggiore S. Giovanni Battista, Heamatology Unit, Turin, IT
P.L. Zinzani, University of Bologna, Institute of Hematology and Oncology L. & A. Seragnoli, Bologna, IT
E. Zucca, Oncology Institute of Southern Switzerland, Department of Medical Oncology, Bellinzona, CH



17 April


Welcome and opening
F. Cavalli, CH - A. Costa, CH and IT

Chairs:M. Gospodarowicz, CA - E. Zucca, CH
 11:10 Primary CNS lymphomas         A.J.M. Ferreri, IT

11:30 Secondary CNS involvement: Who needs, and which type of, CNS              prophylaxis?           C. Thieblemont, FR

 11:45 Pathogenesis of ocular adnexal lymphoma         M. Ponzoni, IT
 12:05 Marginal-zone B-cell lymphomas         E. Zucca, CH
 12:35 Genito-urinary non-Hodgkin’s lymphoma
          U. Vitolo, IT
 12:55 Primary mediastinal lymphoma           P.W.M. Johnson, UK
13:15Poster session and lunch
14:15Key-note lecture
Molecular pathology of B-cell lymphoma
R. Dalla Favera, US


Chairs: M. Ghielmini, CH - P.W.M. Johnson, UK
 14:45 Extranodal or primary CNS DLBC lymphoma?            C. Ogilvie, UK
 14:55 Intestinal T cell lymphoma        K. Lund, UK

15:05 Primary hepatic low-grade B-cell lymphoma: A case report         E. Huti, AL

 15:15 Surgery and multiple successive chemotherapy helped to achieve a sustainable remission in            patient with advanced MALT lymphoma        E. Shakhnovich, RU
 15:25 A case report of myeloma in gastric MALT lymphoma with   bone marrow(BM) involvement:           Two distinct entities?           L. Tedeschi, IT


Coffee break


Chairs:T. Barbui, IT - B. Lowenberg, NL
 16:00 Key-note lecture
            Is molecular biology something more than occupational therapy for basic scientists?         M.F. Fey, CH
 16:30 Acute myeloid leukaemia         B. Lowenberg, NL
 17:00 Chronic lymphocytic leukaemia
          M. Hallek, DE
 17:30 Myeloproliferative neoplasms Ph negative        T. Barbui, IT

Chairs: M.F. Fey, CH - T.A Lister, UK

 18:00 Bone marrow necrosis: A challenging condition        I. Faustino, PT
 18:10 Relapsing t-acute lymphoblastic leukemia post allogeneic peripheral blood stem cell           transplantation 
         N.R. Tumian, MY

18:20 Acute lymphoblastic leukemia: A case-report of difficult management        J. Savva-Bordalo, PT


18:30 Fludarabine induced hemolytic anemia         M. Elsawy, EG

 18:40S. Salvatore Foundation - Award Ceremony and Lecture 


Violin-piano concert by M.F. Fey and P. Villiger 
 20:00Welcome cocktail 


18 April

Chairs: F. Cavalli, CH - R.A. Stahel, CH
 9:00 Key-note lecture
          New biological determinants in lymphoma       G. Salles, FR
 9:30 Follicular lymphomas
        M. Ghielmini, CH
 9:50 Diffuse large B-cell lymphoma
        G. Salles, FR

10:10 T-cell lymphomas
         P.L. Zinzani, IT

 10:30  Coffee break
 10:50 Mantle-cell lymphoma
          M. Dreyling, DE

11:10 Autologous transplantation in lymphoma:Has rituximab changed the scenario?
          J.O. Armitage, US 


11:35 The role of PET
          T.A. Lister, UK

 12:00 Multiple myeloma
          A. Palumbo, IT
Chairs: M.Dreyling, DE - P.L. Zinzani, IT
 12:30 Hodgkin lymphoma with vertebral involvement           C. Ogilvie, UK
 12:40 Pleural effusion in a patient with Hodgkin´s lymphoma        I. Faustino, PT
 12:50 Peripheral T cell lymphoma – Lennert’s subtype           C. Ogilvie, UK

13:00 Peripheral T-cell lymphoma, CMV or both?         A.C. Pinto, PT


An educational activity organized by Prime Oncology and the Pan Pacific Organizers and Faculty
Chairs: J.O. Armitage, US - F. Cavalli, CH
A luncheon symposium organised by 

 13:15 Welcome and introduction
          J.O. Armitage, US - F. Cavalli, CH
 13:20 The 2009 Pan Pacific Lymphoma Conference: Overview and history         J.O. Armitage, US

13:30 Interactive debate 1 - Conservative or aggresive therapy for mantle              cell lymphoma?        Conservative: Michele Ghielmini, MD - Agressive: Martin H. Dreyling, MD, PhD


14:00 Management of follicular lymphoma: will our approach in the near future be conservative or            more agressive?        Gilles Salles, MD, PhD


14:30 Interactive debate 2 - Peripheral T-cell lymphoma:What is the best therapeutic             strategy and when should transplantation be utilized        Pier Luigi Zinzani, MD, PhD versus James O. Armitage, MD

 15:00 Panel discussion - Pearls and pitfalls in lymphoma management: Lessons            from Pan Pacific 2009        All faculty
  • Should results of PET imaging done following cycles 2-4 of induction chemotherapy be used for therapeutic decision making?
  • A patient with a stage III diffuse large B-cell lymphoma (including an 11cm para-aortic node mass) is treated with CHOP-R and a complete response results. Would you recommend irradiation to the region of prior bulky disease?
  • What is the best induction regimen for diffuse large B-cell lymphoma?
  • A 52-year-old male patient is diagnosed with chronic lymphocytic leukemia and cytogenetics reveal del(17p.). Which initial therapy would you choose?
  • Which young patients with lymphoma are most likely to benefit from an allotransplant?
 15:35Distribution of CME certificates and departures